Comment
doi: 10.1016/S2213-2600(14)70136-5.
Epub 2014 Jun 24.
The stony road to phe508del CFTR pharmacotherapy: smoothing the first rock
Affiliations
- PMID: 24973279
- DOI: 10.1016/S2213-2600(14)70136-5
Item in Clipboard
Comment
The stony road to phe508del CFTR pharmacotherapy: smoothing the first rock
Lancet Respir Med.
2014 Jul.
No abstract available
Comment on
-
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.Lancet Respir Med. 2014 Jul;2(7):527-38. doi: 10.1016/S2213-2600(14)70132-8. Epub 2014 Jun 24. Lancet Respir Med. 2014. PMID: 24973281 Clinical Trial.
Similar articles
-
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.N Engl J Med. 2015 Oct 29;373(18):1783. doi: 10.1056/NEJMc1510466. N Engl J Med. 2015. PMID: 26510035 No abstract available.
-
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.N Engl J Med. 2015 Oct 29;373(18):1783-4. doi: 10.1056/NEJMc1510466. N Engl J Med. 2015. PMID: 26510034 No abstract available.
-
Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.Drugs Today (Barc). 2016 Apr;52(4):229-37. doi: 10.1358/dot.2016.52.4.2467205. Drugs Today (Barc). 2016. PMID: 27252987 Free PMC article. Review.
-
Another Beginning for Cystic Fibrosis Therapy.N Engl J Med. 2015 Jul 16;373(3):274-6. doi: 10.1056/NEJMe1504059. Epub 2015 May 17. N Engl J Med. 2015. PMID: 25981385 No abstract available.
-
[Treatment of Cystic Fibrosis with CFTR Modulators].Pneumologie. 2016 May;70(5):301-13. doi: 10.1055/s-0042-100607. Epub 2016 Feb 19. Pneumologie. 2016. PMID: 26894479 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
